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	 Three	 simple,	 accurate	 and	 validated	 spectrophotometric	 methods	 were	 developed	 for	 the
determination	of	pyridostigmine	bromide	(PB)	in	presence	of	its	alkaline‐induced	degradation
product,	 3‐hydoxy‐N‐methylpyridinium	 bromide	 (3‐OH	 NMP)	 in	 powder	 form	 and	 in
pharmaceutical	 formulations.	 Method	 A,	 is	 first	 derivative	 method	 (1D),	 which	 is	 based	 on
measuring	the	peak	amplitude	of	the	first	derivative	spectra	(1D)	of	PB	at	260	nm.	Method	B,	is
first	derivative	of	ratio	spectra	(1DD)	which	allows	the	determination	of	PB	at	267.4	nm	using
(50	µg/mL)	of	3‐OH	NMP	as	a	suitable	devisor.	Finally,	method	C	depends	on	mean	centering
of	ratio	spectra	(MCR)	of	PB	with	different	concentrations,	which	were	recorded	over	200‐400
nm	and	divided	by	the	spectrum	of	20	µg/mL	of	3‐OH	NMP	as	a	devisor.	The	obtained	ratio
spectra	were	mean	 centered	 and	 the	 concentrations	 of	 PB	were	 then	 determined	 from	 the
calibration	graphs	obtained	by	measuring	the	amplitudes	at	338	nm.	The	proposed	methods
were	 successfully	 applied	 for	 assay	 of	 PB	 both	 in	 pure	 form	 and	 in	 pharmaceutical
formulations.	 The	 proposed	 methods	 were	 validated	 in	 compliance	 with	 International
Conference	 on	 Harmonization	 (ICH)	 guidelines.	 The	 results	 obtained	 by	 the	 developed
methods	were	statistically	compared	to	those	obtained	by	the	reported	HPLC	method	using	F‐
and	student's	t‐tests	showing	no	significant	difference	regarding	both	accuracy	and	precision.	KEYWORDS	
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1.	Introduction	
	
Pyridostigmine	 bromide,	 3‐[(dimethylcarbamoyl)oxy]‐1‐
methylpyridinium	 bromide,	 [1,2]	 is	 parasypathomimetic	 and	
reversible	choline	esterase	inhibitor	[3],	which	is	used	to	treat	
muscle	weakness	in	people	with	myasthenia	gravis	[4,5].	Since	
it	 is	 a	quaternary	 amine,	 it	 is	poorly	 absorbed	 in	 the	 gut	 and	
does	 not	 cross	 the	blood‐brain	 barrier,	 except	 possibly	 in	
stressful	 conditions	 [6].	 In	military	medicine,	PB	 is	 used	 as	 a	
prophylactic	 agent	 against	 intoxication	 with	 irreversible	
organophosphorus	AChE	 inhibitors,	 such	 as	 the	 nerve	 agents	
sarin	 and	 soman	 [6].	 The	 chemical	 structure,	 molecular	
formula	 and	 molecular	 weight	 are	 shown	 in	 Figure	 1.	 The	
literature	survey	reveals	several	methods	for	determination	of	
PB	 including	spectrophotometry	 [7],	HPLC	[8‐11],	GC	 [12‐15]	
and	CE	[16‐18].	
PB	 is	 determined	 in	 the	 British	 pharmacopoeia	 via	HPLC	
method	 [1].	 PB	 was	 also	 assayed	 in	 presence	 of	 its	 alkaline	
induced	 degradation	 product	 via	 radioisotoptic	 techniques	
[19‐21]	 and	HPLC	methods	 [22‐25].	 Since	 it	 is	 very	 liable	 to	
hydrolytic	degradation,	 it	 is	degraded	 in	 the	alkaline	solution	
into	 3‐hydroxy‐N‐methylpyridinium	 bromide	 as	 shown	 in	
Figure	1	 and	various	analytical	 techniques;	mainly	HPLC	and	
GC	 have	 been	 utilized	 for	 their	 determination	 in	 biological	
samples	[26].	
	
 
Figure	1.	Alkaline	hydrolysis	of	pyridostigmine	bromide. 
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The	novelty	of	the	presented	work	lies	in	development	and	
validation	 of	 three	 new	 spectrophotometric	 methods	 for	
determination	 of	 PB	 in	 presence	 of	 its	 alkaline	 degradation	
product,	 namely;	 first	 derivative,	 first	 derivative	 of	 ratio	
spectra	 and	 mean	 centering	 of	 ratio	 spectra.	 The	 proposed	
methods	 are	 simple,	 rapid,	 don't	 require	 preliminary	
separation	steps	and	can	be	used	easily	for	the	analysis	of	PB,	
especially	in	quality	control	laboratories.	
	
2.	Experimental	
	
2.1.	Instrumentations	
	
A	double	 beam	UV‐visible	 spectrophotometer	 (Shimadzu,	
Japan)	model	UV‐1601	PC	with	quartz	cell	of	1	cm	path	length	
was	connected	to	IBM	compatible	computer.	The	software	was	
UV‐PC	 personal	 spectroscopy	 software	 version	 3.7.	 Data	
analyses	were	accomplished	with	support	of	PLS‐Toolbox	2.0	
running	under	Matlab®,	version	7.1.	
	
2.2.	Materials	
	
2.2.1.	Pure	standard	
	
Pyridostigmine	 bromide	 was	 kindly	 supplied	 by	
Alexandria	 Company	 for	 Pharmaceuticals	 &	 Chemical	
Industries,	 Alexandria,	 Egypt.	 Its	 purity	 was	 found	 to	 be	
100.46%	according	to	the	established	method	[1].	
	
2.2.2.	Pharmaceutical	formulations	
	
Pystonin®	 sugar	 coated	 tablets	 (Batch	No.	 4163002)	 are	
labeled	 to	 contain	 60	 mg	 of	 pyridostigmine	 bromide,	
manufactured	by	Alexandria	Company	 for	Pharmaceuticals	&	
Chemical	Industries,	Alexandria	City,	Egypt.	Mestinon®	tablets	
(Batch	 No.	 80085169)	 are	 labeled	 to	 contain	 60	 mg	 of	
pyridostigmine	 bromide,	 manufactured	 by	 Valeant	 Pharma‐
ceuticals	Switzerland	GMBH,	Birsfelden,	Switzerland.	
	
2.2.3.	Chemicals	and	reagents	
	
All	chemicals	used	throughout	this	work	were	of	analytical	
grade,	and	the	solvents	were	of	spectroscopic	grade	(Methanol	
and	hydrochloric	acid,	Merck,	Germany).	
	
2.3.	Standard	solutions	
	
Working	 standard	 solutions	 of	 PB	 and	 3‐OH	 NMP	 (100	
µg/mL)	were	prepared	by	a	suitable	dilution	of	stock	solutions	
(1	mg/mL	 in	methanol)	 of	 each	 component	with	 0.05	 N	HCl	
solutions.	All	 stock	 standard	 solutions	were	 freshly	prepared	
on	 the	 day	 of	 analysis	 and	 stored	 in	 refrigerator	 to	 be	 used	
within	24	h.	
	
2.4.	Laboratory	prepared	mixtures	
	
Different	mixtures	containing	different	ratios	of	PB	and	3‐
OH	 NMP	 were	 prepared	 using	 their	 respective	 working	
solutions	(100	µg/mL).	
	
2.5.	Preparation	of	degradation	product	
	
An	 accurately	weighted	 amount	of	PB	powder	 equivalent	
to	0.5	g	was	dissolved	in	15	mL	of	0.1	N	sodium	hydroxide	and	
the	 solution	 was	 left	 for	 30	 min.	 at	 room	 temperature.	
Appropriate	 volume	 of	 the	 resultant	 solution	was	 applied	 on	
TLC	 plate	 where	 complete	 degradation	 was	 followed	 up	 via	
TLC	using	methanol‐ethyl	acetate‐triethyl	amine‐glacial	acetic	
acid	 (9:1:	 0.5:0.05;	 v:v:v:v)	 as	 a	 developing	 system.	 After	
complete	degradation,	the	degradation	product	was	extracted	
three	 times	 each	 with	 50	mL	 diethyl	 ether.	 The	 extract	 was	
then	 evaporated	 at	 room	 temperature	 to	 dryness.	 The	
degradation	 product	 powder	 was	 dried	 and	 identified	 by	 IR	
and	Mass	spectrometry	as	shown	in	Figure	2b,	and	Figure	3b,	
respectively,	and	used	for	preparation	of	the	stock	solution	of	
the	 degradation	 product.	 PB	 was	 exposed	 to	 other	 stress	
conditions	 such	 as	 acid	 hydrolysis,	 oxidation	 and	
photodegradation.	Acid	hydrolysis	was	carried	out	with	0.1	N	
HCl	at	room	temperature	and	80	°C	for	3	hrs.	Oxidation	studies	
were	 implemented	 using	 30%	 hydrogen	 peroxide	 solution.	
Finally,	 photochemical	 stability	 was	 studied	 by	 exposing	 the	
drug	 sample	 to	 daylight	 for	 24	 hrs.	 PB	 showed	 stability	
regarding	 acid	 hydrolysis,	 oxidation	 and	 photo‐stability	
studies.	
	
(a)	
	
	(b)	
	
Figure	2. IR	spectrum	of	PB	(a)	and	3‐OH	NMP	(b).
	
	
	
(a)	
	
	
(b)	
	
Figure	3.Mass	spectrum	of	PB	(a)	and	3‐OH	NMP	(b).
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2.6.	Procedures	
	
2.6.1.	Spectral	characteristics	of	PB	and	PB	degradation	
product	
	
Zero	order	absorption	spectra	of	10	μg/mL	each	of	PB	and	
3‐OH	NMP	were	 recorded	 from	200	 to	 400	nm	using	0.05	N	
HCl	as	a	solvent,	Figure	4.	
	
	
	
Figure	 4.	 Zero	 order	 absorption	 spectra	 of	 20	 µg/mL	 of	 PB	 (__)	 and	 20	
µg/mL	of	3‐OH	NMP	(‐‐‐)	using	0.05	N	HCl.	
	
2.6.2.	Linearity	and	construction	of	calibration	curves	
	
2.6.2.1.	First	derivative	spectrophotometric	method	(1D)	
	
Accurately	measured	aliquots	equivalent	to	100‐700	µg	of	
PB	were	 transferred	 from	 its	working	 solution	 (100	 µg/mL)	
into	 a	 series	 of	 10	 mL	 volumetric	 flasks.	 The	 volume	 was	
completed	 with	 0.05	 N	 HCl	 to	 obtain	 a	 final	 concentration	
range	 (10‐70	µg/mL).	 1D	curves	were	 recorded	at	Δλ	=	4	nm	
and	 scaling	 factor	 =	 5.	 The	 peak	 amplitudes	 at	 260	nm	were	
recorded	 then	 calibration	 graph	 was	 constructed.	 The	
regression	equation	was	 then	 computed	 for	 the	 studied	drug	
at	 the	 specified	 wavelength	 and	 used	 for	 determination	 of	
unknown	samples	containing	PB.	
	
2.6.2.2.	First	derivative	ratio	spectrophotometric	method	
(1DD)	
	
Accurately	measured	aliquots	equivalent	to	100‐700	µg	of	
PB	were	 transferred	 from	 its	working	 solution	 (100	 µg/mL)	
into	 a	 series	 of	 10	 mL	 volumetric	 flasks.	 The	 volume	 was	
completed	 with	 0.05	 N	 HCl	 to	 obtain	 a	 final	 concentration	
range	(10‐70	µg/mL).	1DD	curves	were	recorded	at	Δλ	=	4	nm	
and	 scaling	 factor	 =	 10.	 The	 absorption	 spectra	 of	 these	
solutions	 were	 divided	 by	 the	 absorption	 spectrum	 of	 50	
µg/mL	 of	 3‐OH	 NMP	 (as	 a	 divisor),	 then	 the	 obtained	 ratio	
spectra	 were	 differentiated	 with	 respect	 to	 wavelength.	 The	
peak	amplitudes	at	267.4	nm	were	recorded,	then	calibration	
graph	was	constructed	relating	the	peak	amplitudes	of	1DD	to	
the	 corresponding	 concentrations.	 The	 regression	 equation	
was	 then	 computed	 for	 the	 studied	 drug	 at	 the	 specified	
wavelength	 and	used	 for	 determination	of	 unknown	samples	
containing	PB.		
	
2.6.2.3.	Mean	centering	of	ratio	spectra	spectrophotometric	
method	(MCR)	
	
Accurately	measured	aliquots	equivalent	to	100‐700	µg	of	
PB	were	 transferred	 from	 its	working	 solution	 (100	 µg/mL)	
into	 a	 series	 of	10	mL	volumetric	 flasks	 and	 the	 volume	was	
completed	with	0.05	N	HCl	to	final	concentration	range	(100‐
700	µg/mL).	
The	 recorded	absorption	spectra	of	PB	 from	200‐400	nm	
were	 divided	 by	 the	 absorption	 spectrum	 of	 3‐OH	 NMP	 (20	
µg/mL)	 to	 obtain	 the	 ratio	 spectra	 which	 were	 then	 mean	
centered.	 These	mean	 centered	 values	 of	 the	 ratio	 spectra	 at	
338	nm	were	recorded	and	plotted	versus	 the	corresponding	
concentrations.	 Calibration	 curve	 was	 constructed	 and	
regression	equation	was	computed.	
	
2.6.3.	Analysis	of	laboratory	prepared	mixtures	
	
Mixtures	 containing	different	 ratios	of	PB	and	3‐OH	NMP	
10‐90%	were	prepared.	The	volume	was	adjusted	with	0.05	N	
HCl	 solution	 and	 procedures	 mentioned	 under	 Section	 2.6.2	
were	 followed.	 The	 concentrations	were	 calculated	 from	 the	
corresponding	regression	equations.	
	
2.6.4.	Application	to	pharmaceutical	formulations	
(Pystonin®	and	Mestinon®	tablets)		
	
Twenty	tablets	of	each	of	Pystonin®	and	Mestinon®	were	
separately	weighed,	powdered	and	mixed	well.	An	accurately	
weighed	amount	of	the	powdered	tablets	equivalent	to	100	mg	
of	each	pharmaceutical	 formulation	was	 transferred	 into	 two	
separate	100	mL	volumetric	 flasks	and	 then	75	mL	methanol	
was	 added	 to	 each	 flask.	 The	 prepared	 solutions	 were	
sonicated	 for	 30	min,	 cooled	 and	 completed	 to	 volume	with	
methanol	to	obtain	1000	µg/mL	stock	solution.	The	solutions	
were	filtered	and	diluted	with	0.05	N	HCl	to	obtain	100	µg/mL	
working	 solutions	 and	 the	 procedures	 under	 Section	 2.6.2	
were	 followed.	 When	 carrying	 out	 the	 standard	 addition	
technique,	the	powdered	tablets	and	pure	PB	were	mixed	well	
together	 before	 proceeding	 in	 the	 above	 mentioned	
procedures. 
	
3.	Results	and	discussion	
	
PB	 contains	 amide	 group,	which	 is	 liable	 to	hydrolysis	 in	
basic	 condition,	 as	 shown	 in	 Figure	 1.	 The	 first	 degradation	
product	 is	 aliphatic	 compound	 that	 is	 very	 soluble	 in	 water	
and	has	no	absorbance	under	UV,	but	the	second	degradation	
product	 is	 the	 main	 degradation	 product	 [8],	 which	 is	
precipitated	 upon	 hydrolysis	 with	 NaOH	 and	 was	 extracted	
with	 multiple	 fractions	 of	 ether	 in	 our	 study.	 The	 several	
extractions	 were	 collected	 and	 evaporated	 at	 room	
temperature	 and	 the	 degradation	 product	 (3‐OH	 NMP)	
powder	 was	 identified	 by	 IR	 and	 mass	 spectrometry,	 where	
the	 IR	 spectrum	 of	 PB	 Figure	 2a,	 shows	 a	 strong	 band	
corresponding	to	the	amide	carbonyl	group	stretching	at	1736	
cm‐1	(peak	6)	and	a	band	at	2950	cm‐1	(peak	3)	characteristic	
of	 C‐H	 stretching	 of	 the	 aliphatic	 CH3	 in	 PB.	 The	 absence	 of	
these	 two	 characteristic	 bands	 in	 the	 IR	 spectrum	 of	 3‐OH	
NMP	in	addition	to	the	appearance	of	single	stretching	band	at	
3445	 cm‐1	 (peak	 1)	 characteristic	 of	 the	 hydroxyl	 group	 is	
evidence	of	the	cleavage	of	the	carbamate	group	and	complete	
degradation	 of	 the	drug	 at	 the	 stated	 conditions	 as	 shown	 in	
Figure	2b.	
The	 mass	 spectra	 of	 PB	 and	 3‐OH	 NMP	 also	 confirmed	
their	identity	as	mass	molecular	ion	peaks	at	m/z	260	and	190	
corresponding	 to	 the	 intact	 drug	 (PB)	 and	 its	 degradation	
product	(3‐OH	NMP),	respectively,	as	shown	in	Figure	3a	and	
Figure	 3b.	 Thus	 the	main	 task	 of	 this	work	was	 to	 study	 the	
stability	of	PB	according	to	ICH	guidelines	[26]	for:		
i. Stress	 alkaline	 hydrolysis:	 0.1	 N	 NaOH	 at	 room	
temperature	for	30	min.		
ii. Stress	acid	hydrolysis:	0.1	N	HCl	at	80	°C	for	3	h.	
iii. Oxidative	condition:	30%	H2O2	for	24	hrs.	
iv. Photochemical	 stability	 was	 studied	 by	 exposing	 the	
drug	sample	to	daylight	for	24	hrs.	
PB	 showed	 stability	 regarding	 acid	 hydrolysis,	 oxidation	
and	photo‐stability	studies.	
PB	 acts	 as	 parasypathomimetic	 and	 reversible	 choline	
esterase	 inhibitor	which	has	been	used	 in	 treatment	of	 some	
serious	 diseases	 such	 as	 myasthenia	 gravis,	 hence	 it	 is	 very	
important	to	develop	some	methods	which	not	only	are	rapid,	
accurate,	 precise,	 but	 also	 simple	 and	 economic	 for	
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determination	of	the	studied	drug	in	its	pharmaceutical	dosage	
forms	 and	 this	 was	 the	 main	 task	 of	 the	 developed	
spectrophotometric	methods.	
UV‐spectrophotometric	 methods	 of	 analysis	 have	
advantages	 of	 saving	 time	 and	 cost	when	 compared	 to	 other	
methods	such	as	HPTLC	and	HPLC	methods	[27,28].	This	work	
concerns	with	the	development	of	three	accurate,	precise	and	
rapid	 spectrophotometric	 methods	 namely;	 first	 derivative	
(1D),	first	derivative	of	ratio	spectra	(1DD)	and	mean	centering	
of	 ratio	 spectra	 (MCR)	 for	 analysis	 of	 PB	 in	 presence	 of	 its	
alkaline	induced	degradation	product.	
	
3.1.	Spectrophotometric	methods	optimization	
	
One	 of	 the	 important	 steps	 in	 development	 of	 analytical	
methods	 is	 to	 optimize	 the	 parameters,	 variables	 and	
conditions	 which	 will	 be	 followed	 in	 development	 and	
validation	to	obtain	the	best	results.		
To	 optimize	 the	 1D,	 1DD	 and	 mean	 centering	
spectrophotometric	 methods,	 it	 was	 important	 to	 test	 the	
influence	of	the	following	variables:	
	
3.1.1.	Solvents	
	
Different	solvents	were	experimented	(methanol,	ethanol,	
isopropanol,	acetonitrile,	purified	water,	0.05	N	HCl	and	0.1	N	
HCl).	It	was	found	that	PB	is	stable	in	these	solvents	and	0.05	N	
HCl	 was	 the	 best	 solvent	 regarding	 both	 sensitivity	 and	
selectivity.	
	
3.1.2.	The	divisor	and	its	concentration	
	
The	 effect	 of	 divisor	 concentration	 on	 the	 method	
selectivity	 and	 analytical	 parameters	 such	 as	 intercept,	 slope	
and	correlation	coefficient	of	calibration	equations	was	tested.	
Different	concentrations	of	3‐OH	NMP	were	tested	as	a	divisor	
(10,	20,	30,	40	and	50	µg/	mL).	It	was	found	that	50	µg/mL	of	
3‐OH	NMP	was	the	best	concentration	 in	case	of	 1DD	method	
and	20	µg/mL	of	3‐OH	NMP	was	the	best	concentration	in	case	
of	MCR	method	regarding	both	selectivity	and	sensitivity.	
	
3.1.3.	Smoothing	and	scaling	factors		
	
Different	smoothing	factor	(Δλ)	values	were	 tried	such	as	
(2,	4	and	8),	where	smoothing	factor	=	4	presented	a	suitable	
signal	 to	 noise	 ratio	with	 good	 resolution	 in	 case	 of	 both	 1D	
and	1DD.	Different	scaling	factor	values	were	tried	such	as	(10,	
5	and	100),	where	scaling	 factor	=	5	and	10	were	 the	best	 in	
case	 of	 1D	 and	 1DD	 respectively	 to	measure	 the	 signal	 of	 PB	
and	to	decrease	the	reading	error.	
	
3.2.	1D	spectrophotometric	method	
	
The	 zero‐order	 absorption	 spectra	 of	 PB	 and	 its	
degradation	 product	 3‐OH	 NMP	 display	 sever	 overlapping	
Figure	4,	which	interferes	with	the	direct	spectrophotometric	
determination	 of	 PB	 in	 presence	 of	 its	 degradate.	 Derivative	
spectrophotometry	 is	 an	 analytical	 technique	 of	 great	 utility	
for	 resolving	 the	 overlapped	 spectra.	 The	 application	 of	 this	
technique	provides	selective	determination	of	PB	 in	presence	
of	3‐OH	NMP,	by	measuring	the	peak	amplitude	at	260	nm	as	
shown	in	Figure	5.	
The	peak	amplitude	of	the	first	derivative	spectrum	at	λ	=	
260	 nm	 as	 shown	 in	 Figure	 6	 was	 plotted	 versus	 the	
concentration	 of	 PB	 in	 the	 range	 of	 10‐70	 µg/mL.	 The	
calibration	 curve	 was	 constructed	 with	 mean	 percentage	
recovery	 99.76±1.526.	 The	 following	 linear	 regression	
equation	was	obtained:		
	
Y	=	0.0042	×	C	+	0.0019		 r	=	0.9997	 	 (1)	
	
where	 Y	 is	 the	 peak	 amplitude	 at	 260	 nm,	 C	 is	 the	
concentration	in	µg/mL	and	r	is	the	correlation	coefficient.		
	
	
 
Figure	5.	First	derivativa	spectra	of	10	µg/mL	of	PB	(__)	and	50	µg/mL	of	3‐
OH	NMP	(‐‐‐)	using	0.05	N	HCl	as	blank.	
	
	
	
Figure	6. First	derivative	spectra	of	PB	(____)	in	the	range	of	10‐70	µg/mL	
using	0.05	N	HCl	as	blank.	
	
3.3.	1DD	spectrophotometric	method	
	
First	derivative	ratio	spectrophotometry	has	the	ability	to	
overcome	the	problem	of	overlapping	spectra.	The	application	
of	 this	 technique	 allows	 selective	 determination	 of	 PB	 in	
presence	 of	 3‐OH	 NMP	 by	 measuring	 the	 peak	 amplitude	 at	
267.4	nm	as	shown	in	Figure	7.	The	absorption	spectrum	of	PB	
was	divided	by	the	absorption	spectrum	of	50	µg/mL	of	3‐OH	
NMP	(as	a	divisor),	and	then	the	obtained	ratio	spectrum	was	
differentiated	with	respect	to	wavelength.	The	peak	amplitude	
of	the	first	derivative	ratio	spectrum	at	λ	=	267.4	nm,	as	shown	
in	Figure	8,	was	plotted	versus	the	concentration	of	PB	in	the	
range	of	10‐70	µg/mL.		
	
	
	
Figure	7.	First	derivative	of	ratio	spectra	of	10µg/mL	of	PB(__)	and	10µg/ml	
of	3‐OH	NMP(‐‐‐)	using	50	µg/mL	of	3‐OH	NMP	as	a	devisor	and	0.05	N	HCl	
as	blank.	
	
 
	
	
Figure	 8.	 First	 derivative	 of	 ratio	 spectra	 of	 of	 PB	 in	 the	 range	 of	 10‐70	
µg/mL	using	50	µg/	mL	3‐OH	NMP	as	a	divisor	and	0.05	N	HCl	as	blank.	
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Table	1.	Assay	results	for	the	determination	of	PB	in	synthetic	mixtures	with	3‐OH	NMP	prepared	to	contain	10‐90%	degradate.	
3‐OH	NMP	%	 %	Recovery		 %	Recovery	 %	Recovery	
1	D	spectrophotometric	method	 1 DD	spectrophotometric	method Mean	centering	method
10%	 98.86	 98.96	 99.86	
20%	 101.54	 101.28 101.57	
30%	 102.32	 99.30	 100.19	
40%	 100.73	 101.63	 100.88	
50%	 102.32	 98.36	 100.63	
60%	 102.20	 101.70 99.05	
70%	 102.60	 99.72 99.85	
80%	 100.85	 99.85 98.90	
90%		 93.59*	 100.36 92.54*	
Mean±SD	 101.43±1.251	 100.13±1.200 100.12±0.903		
* Rejected	value.	
	
	
The	 calibration	 curve	 was	 constructed	 with	 mean	
percentage	 recovery	 99.90±0.762.	 The	 following	 linear	
regression	equation	was	obtained:		
	
Y	=	0.0260	×	C	+	1.1613		 r	=	0.9999	 	 (2)	
	
where	 Y	 is	 the	 peak	 amplitude	 at	 267.4	 nm,	 C	 is	 the	
concentration	in	µg/mL	and	r	is	the	correlation	coefficient.	
	
3.4.	Mean	centering	of	ratio	spectra	spectrophotometric	
method	(MCR)	
	
The	 developed	 MCR	 method	 depends	 on	 the	 mean	
centering	of	the	ratio	spectra,	it	gets	rid	of	the	derivative	steps	
and	 therefore	 signal‐to‐noise	 ratio	 is	 increased	 [29].	 This	
method	 is	 able	 to	 resolve	 binary	 and	 ternary	 mixtures	 in	
complex	 samples	 with	 unknown	 matrices	 [30].	 The	
mathematical	 explanation	 of	 this	 method	 was	 discussed	 and	
illustrated	by	Afkhami	and	Bahram	[31‐33].	
The	 absorption	 spectra	 of	 PB	 were	 recorded	 in	 the	
wavelength	 range	 of	 200‐400	 nm	 and	 divided	 by	 the	
absorption	spectrum	of	20	µg/mL	of	3‐OH	NMP	to	obtain	the	
ratio	 spectra	 which	 were	 then	 mean	 centered.	 PB	 was	
determined	by	measuring	the	peak	amplitude	at	338	nm	which	
corresponds	 to	 maximum	wavelength	 as	 shown	 in	 Figure	 9.	
The	 peak	 amplitude	 was	 plotted	 versus	 the	 corresponding	
concentration	 in	 the	 range	 of	 10‐70	 µg/mL.	 The	 calibration	
curve	 was	 constructed	 with	 mean	 percentage	 recovery	
99.91%±1.343.	 The	 following	 linear	 regression	 equation	was	
obtained:		
	
Y	=	0.4626	×	C	+	0.6773		 r	=	0.9998	 	 (3)	
	
where	 Y	 is	 the	 peak	 amplitude	 at	 338	 nm,	 C	 is	 the	
concentration	in	µg/mL	and	r	is	the	correlation	coefficient.	
	
	
	
Figure	9.	The	mean	centered	ratio	absorption	spectra	of	PB	in	the	range	of	
10‐70	µg/mL	using	0.05	N	HCl	as	blank. 
3.5.	Stability‐indication	and	selectivity	
	
The	 assessment	 of	 the	 stability‐indicating	 efficiency	 and	
selectivity	of	the	proposed	methods	was	proved	by	application	
of	 these	methods	 to	 laboratory	prepared	mixtures	containing	
different	ratios	of	PB	and	3‐OH	NMP.	Results	given	in	Table	1	
indicate	 that	 three	 proposed	 methods	 are	 valid	 for	
determination	of	 intact	PB	in	presence	of	 its	alkaline‐induced	
degradation	product.	Compared	to	the	derivative	method,	MCR	
eliminates	the	derivative	step	and	so	the	signal‐to‐noise	ratio	
is	enhanced.	
As	the	suggested	methods	could	effectively	determine	the	
drug	 in	 presence	 of	 its	 degradate	 (3‐OH	 NMP),	 they	 can	 be	
employed	as	stability	indicating	ones.	
	
3.6.	Application	of	the	proposed	methods	to	the	
pharmaceutical	formulation	
	
The	 suggested	methods	were	 successfully	 applied	 for	 the	
assay	of	PB	in	its	pharmaceutical	formulations	(Pystonin®	and	
Mestinon®	tablets),	showing	good	percentage	recoveries.	The	
validity	 of	 the	 developed	 methods	 was	 further	 assessed	 by	
applying	 the	 standard	 addition	 technique	 and	 confirmed	 the	
accuracy	of	the	methods	as	shown	in	Table	2.	
	
3.7.	Methods'	validation 
	
The	 international	 conference	 on	 harmonization	 (ICH)	
guidelines	 [34]	 for	 analytical	 method	 validation	 has	 been	
followed	throughout	methods'	validation.	
	
3.7.1.	Linearity	
	
Under	 optimum	 experimental	 conditions,	 PB	 was	
determined	 in	 triplicates	 in	 the	range	of	10‐70	µg/mL	 for	 1D,	
1DD	and	MCR,	Table	3.	
	
3.7.2.	Accuracy	
	
The	 accuracy	 of	 the	 proposed	methods	was	 checked	 by	
determination	of	different	blind	samples	of	PB.	The	accuracy	
was	ascertained	also	by	application	of	the	standard	addition	
technique	 and	 through	 analysis	 of	 market	 pharmaceutical	
preparation	by	the	suggested	methods.	The	good	percentage	
recoveries	 of	 pure	 drug	 samples	 provide	 good	 accuracy	 of	
the	proposed	methods,	Table	2.	
	
3.8.	Precision	
	
3.8.1.	Repeatability	
	
Three	 different	 concentrations	 of	 PB	 (20,	 30	 and	 40	
µg/mL)	for	1D	method,	(10,	60,	70	µg/mL)	for	1DD	method	and	
(10,	 20,	 30	 µg/mL)	 for	 MCR	 method	 were	 determined	 in	
triplicates	in	the	same	day	to	estimate	intraday	variation.		
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Table	2.	Determination	of	pyridostigmine	bromide	in	pharmaceutical	formulations	by	the	proposed	methods	and	application	of	standard	addition	technique	
Method	 Pharmaceutical	formulation	 Taken	(µg/mL)	 Found	%	±	SD	 Pure	added	(µg	/mL)	 Recovery%		
1D	method	 Pystonin®	tablets	
Batch.	No	(4163002)	
20 101.46±1.004
	
10 99.76
20 101.59
30 101.38
Mean±SD	 100.91±1.003
Mestinon®	tablets	
Batch.	no	(80085169)	
20 96.83±1.578
	
10 100.00
20 98.05
50 99.61
Mean±SD	 99.22±1.032
1DD	method	 Pystonin®	tablets	
Batch.	No	(4163002)	
20 96.48±1.315 10 100.69
40 99.09
50 101.53
Mean±SD	 100.44±1.238
Mestinon®	tablets	
Batch.	no	(80085169)	
20	 94.99±0.995	 8	 102.07	
10	 99.13	
12 98.91
Mean±SD	 100.04±1.764
Mean	centring	method	 Pystonin®	tablets	
Batch.	No	(4163002)	
20	 98.84±1.229	 15 99.72
20	 97.64	
25	 100.05	
Mean±SD	 99.14±1.302	
Mestinon®	tablets	
Batch.	no	(80085169)	
20	 96.25±1.233	 10	 98.51	
15	 101.88	
25 101.32
Mean±SD	 100.57±1.808	
	
	
Table	3.	Regression	and	analytical	validation	parameters	of	the	proposed	methods	for	determination	of	PB	in	presence	of	3‐OH	NMP.	
Parameter	 1D	spectrophotometric	method 1DD	spectrophotometric	method Mean	centering	method	
Calibration	range	(µg/mL)	 10‐70		 10‐70		 10‐70	
Slope	 0.0042	 0.2602	 0.4626	
Intercept	 0.0014	 1.1613	 0.6773	
Correlation	coefficient	(r)	 0.9997	 0.9999 0.9998	
Accuracy,	%	 99.76±1.526	 99.90±0.762 99.91±1.343	
Specificity	and	Selectivity	 101.43±1.251	 100.13±1.200 100.12±0.903	
Precision	 	
Repeatability	(RSD%)	*	 1.354	 0.918 0.400	
Intermediadte	Precision	(RSD%)	*	 1.733	 1.299 1.480	
LOD	**	(µg/mL)	 2.406		 2.872	 2.748	
LOQ	**	(µg/mL)	 7.314		 9.479	 9.069	
*	RSD%	and	RSD%;	the	intra‐	and	inter‐day	relative	standard	deviation	of	concentrations	(20,30	and	40	µg/	mL)	for	1D	method,	(10,	60	and	70	µg/mL)	for	1DD	
method	and	(10,	20	and	30	µg/mL)	for	MCR	method.	
**	Limit	of	detection	and	quantitation	are	determined	via	calculations	for	1	D,	1DD	and	MCR	methods	(LOD	=	3.3	×	SD/slope,	LOQ	=	10	×	SD/slope)	[26].	
	
	
Table	4.	Statistical	analysis	of	the	three	proposed	methods	(1D	spectrophotometric	method,	1DD	spectrophotometric	method	and	Mean	centering	method)	and	
the	reported	HPLC	method	for	determination	of	PB	in	presence	of	its	alkaline‐induced	degradation	product.	
Parameters	 1D	method	 1DD	method Mean	centering	method Reported	HPLC	method	[1]
Mean	 99.85	 99.90 99.91 100.46	
SD	 1.635	 0.929 1.343 0.718	
Variance	 2.673	 0.863 1.804 0.515	
n	 7	 7 7 7	
Student’s	t‐test	(2.45)	*	 0.384	 0.238 0.366 -	
F‐	test	(4.28)	*	 3.049	 1.676 3.503 - 
*	The	values	between	parenthesis	are	corresponding	to	the	theoretical	values	of	t	and	F	(p	=	0.05).	
	
	
Good	 percentage	 recoveries	 and	 acceptable	 relative	
standard	 deviation	 (RSD%)	 values	were	 obtained	 confirming	
the	repeatability	of	the	three	methods	Table	3.	
	
3.8.2.	Intermediate	precision	
	
The	 previous	 procedures	 were	 repeated	 on	 the	 same	
concentrations	 on	 different	 five	 days	 to	 determine	 the	
intermediate	 precision.	 Good	 results	 and	 acceptable	 relative	
standard	deviation	(RSD%)	are	shown	in	Table	3.	
	
3.9.	Specificity	
	
Specificity	of	the	method	was	tested	by	how	accurately	and	
specifically	the	analyte	of	interest	is	determined	in	presence	of	
other	components	(impurities,	degradates	or	excipients)	[34].	
It	was	achieved	by	analysis	of	different	synthetic	 laboratory	
prepared	 mixtures	 containing	 different	 ratios	 of	 PB	 spiked	
with	appropriate	levels	of	3‐OH	NMP;	demonstrating	that	the	
assay	 results	 are	 unaffected	 by	 the	 presence	 of	 3‐OH	 NMP	
and	 confirming	 the	 specificity	 of	 the	 proposed	 methods	 as	
shown	in	Table	1.	
	
3.10.	Limits	of	detection	and	quantitation	(LOD	and	LOQ)	
[34]	
	
The	 approach	 based	 on	 the	 standard	 deviation	 of	 the	
response	and	the	slope	was	used	for	determining	the	detection	
and	quantitation	limits,	Table	3.	
	
LOD	=	3.3	×	SD	/	slope		 	 	 	 (4)	
	
LOQ	=	10	×	SD	/	slope		 	 	 	 (5)	
	
Acceptable	detection	and	quantitation	limits	are	shown	in	
Table	3.	
The	 statistical	 comparison	 of	 the	 results	 obtained	 by	 the	
proposed	methods	and	those	obtained	by	the	reported	method	
on	the	pure	PB	as	shown	in	Table	4	indicating	that	there	is	no	
significant	difference	between	the	proposed	methods	and	the	
reported	one	with	respect	to	accuracy	and	precision.	
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4.	Conclusion	
	
The	 presented	 work	 provides	 simple,	 accurate	 and	
selective	 analytical	 methods	 for	 determination	 of	 PB	 in	
presence	of	 its	degradation	product	which	 is	 separated	upon	
alkaline	 hydrolysis	 of	 PB	 both	 in	 bulk	 powder	 and	 in	
pharmaceutical	 formulations.	 The	 developed	 methods	 are	
found	to	be	rapid,	simple,	accurate,	reproducible,	selective	and	
easy	 to	 apply.	 The	 suggested	 methods	 also	 allowed	 the	
quantitative	 determination	 of	 PB	 and	 its	 degradate	 without	
prior	 separation.	 Compared	 to	 the	 derivative	 method,	 MCR	
eliminates	the	derivative	steps.		
Application	 of	 the	 proposed	 methods	 to	 assay	 of	 PB	 in	
laboratory‐prepared	 mixtures	 and	 pharmaceutical	 formula‐
tions	 shows	 that	 neither	 the	 alkaline‐induced	 degradation	
product	nor	 the	additives	 interfere	with	the	determination	of	
PB;	indicating	that	the	proposed	methods	could	be	applied	as	
stability	 indicating	methods	for	the	determination	of	pure	PB	
and	 in	 the	 presence	 of	 its	 alkaline‐induced	 degradation	
product	 either	 in	 bulk	 powder	 or	 in	 pharmaceutical	
formulations.	
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